{
  "docId": "019de074-abc1-773c-9c2f-d49993e7b79a",
  "docSlug": "59a1ae16b5e60c748be3b046cd750424",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 20 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4138439,
  "pageNumber": 9,
  "pageCount": 20,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes a testimonial from Puja Sapra and a list of pipeline assets.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-abc1-773c-9c2f-d49993e7b79a/9",
  "deckHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a",
  "deckJsonHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a.json",
  "deckAnchorHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "ADC component assembly: Targets/antibodies + Linkers + Warhead",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fe8d27a-742a-465d-8c2d-199983ee19a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "1. Biomarkers 2. Mechanistic and IO combinations 3. Understanding resistance",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b552ff4-5c61-4189-998a-1c6b2a58c48b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Puja Sapra, Senior Vice President, Biologics Engineering & Targeted Delivery, Oncology Research & Development",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8d1fee5-22cc-4ef6-b472-ee86011a5687",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "quote",
      "text": "It's been an incredible few years as we have established our in-house ADC capabilities...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e615153b-4fc3-49f8-a8a9-71cb1ae3fb1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "cMET, mesenchymal-epithelial transition factor; EGFR, epidermal growth factor receptor; FRa, folate receptor alpha; IO, immuno-oncology; MMAE, monomethyl auristatin E; TOP1i, topoisomerase 1 inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "566a68b4-9110-4f53-840f-246911af9019",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.65
      },
      "kind": "table",
      "text": "AstraZeneca in-house ADC pipeline: Phase I: AZD8205, AZD9592, CMG901; Preclinical: AZD5335",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "240cd23f-27cc-4357-939d-6d8377ce27e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Leveraging in-house ADC capabilities and technology to accelerate innovation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e929c75-be06-4e85-abe9-3e7d009dbe7e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "56cdd0e4-2e0f-4301-9ad2-c8da972ed7de",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Details on novel treatments and pipeline advancements aim to satisfy the need with solutions.",
      "position": 3,
      "confidence": 0.7,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 7,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "3287b1c0-2747-4dd0-ac7f-c89f27fd4924",
      "evidence": "The focus on proprietary ADC technology and pipeline advancements.",
      "position": 1,
      "objective": "How can AstraZeneca deliver innovative treatments for resectable lung cancer and other solid tumors?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}